English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/122477
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease

Other TitlesTriazinones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease
AuthorsPrati, Federica; Pérez, Daniel I.; Pérez Castillo, Ana ; Martínez, Ana ; Bolognesi, Maria Laura
KeywordsAlzheimer’s disease
6-amino-3
4-dihydro-1
3,5-triazin-2(1H)-one
Drug design
Multitarget-directed ligands
Multitarget drug discovery
Issue Date14-Jul-2015
PublisherAmerican Chemical Society
CitationACS Chem. Neurosci., Article ASAP
AbstractOne of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathology. Therefore, the use of multitarget-directed ligands has emerged as particularly suitable. Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come. In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compound 1 showed interesting properties in a preliminary investigation. Notably, compound 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, respectively), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays. It also showed good brain permeability in a pharmacokinetic assessment in mice. Overall, triazinone derivatives, thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer’s disease models.
Description72 p.-7 fig.-2 tab.-4 sch. Prati, Federica et al.
Publisher version (URL)http://dx.doi.org/ 10.1021/acschemneuro.5b00121
URIhttp://hdl.handle.net/10261/122477
DOI10.1021/acschemneuro.5b00121
ISSN1948-7193,
E-ISSN1948-7193
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
acs chem. neur._Martínez, Ana_2015(post).pdfPostprint1,78 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.